Short-term effects of tacrilimus in patients with Alport syndrome

YAO Xiao-dan,CHEN Xin,HUANG Gao-yuan,XU Shu-tian,HUANG qian,ZENG Cai-hong,CHEN Hui-ping,HU Wei-xin,LIU Zhi-hong

DOI: https://doi.org/10.3969/j.issn.1006-298X.2011.04.007

2011-01-01

Abstract:Objective:To evaluate the short term effects of tacrolimus(FK506),a kind of calcineurin inhibitors,in patients with Alport syndrome.Methodology:Five 5 cases with Alport syndrome who proved non-responsive to ACEI and traditional Chinese herbal medicine were enrolled this study.All of them were performed percutanious biopsy and satisfied the Flinter's diagnostic criteria for Alport syndrome,and had pathologic evidence of collagen IV chains abnormalities both in kidney and/or skin biopsy specimen.They were 4 male and one female with an average age of 18.5 years old.Their inheritance modes were 4 X-linkage and one autosomal recessive AS(ARAS).FK506 was administered at a dosage of 0.15 mg/(kg·d) for the first 8 weeks and then tapered to 0.10 mg/(kg·d) for the maintenance therapy.The target trough serum concentration of FK506 was 5～8 ng/dl.The efficacy and side-effects of FK506 were observed at an interval of 2～4 weeks during the follow-up.Results:In 4 of the five patients whose CYP3A5 polymorphic genotypes were 2 of CYP3A5-*1/*3,one of CYP3A5-*3/*3 and one of CYP3A5-*1/*1,the target trough level of FK506 was achieved in the proposed therapeutic window range,except one patient of CYP3A5-*1/*1 genotype.In the end of the second and the fourth week of follow-up,a marked reduction of 24-hour urinary protein excretion,and an elevation of serum albumin level were observed in all of patients.Two cases withdrew FK506 because of side-effects as renal toxicity and/or abnormal glucose metabolism.One patient dropped out of the study because of inefficacy associated with failure to achieve targeted trough serum level of FK506.Another 2 patients prolonged the therapy of FK506 for 36 weeks and 40 weeks showed that the level of serum albumin maintained at 33～35 g/L and proteinuria fluctuating between 0.5～2.5 g/L.The side-effects of renal toxicity,gastro-intestinal disorders,and abnormality of glucose metabolism were observed during the first 8 weeks.Conclusion:The proteinuria and hypoalbuminemia was improved by the short term of FK506 therapy in the patients with Alport syndrome.The long-term efficacy of FK506 therapy for patients with Alport syndrome remained further investigation.